 Nikita Pozdeyev
Concepts (293)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 11 | 2024 | 262 | 2.770 |
Why?
| | Thyroid Carcinoma, Anaplastic | 4 | 2020 | 34 | 1.590 |
Why?
| | Retina | 12 | 2012 | 267 | 1.060 |
Why?
| | Thyroid Nodule | 1 | 2024 | 37 | 0.900 |
Why?
| | Adrenal Cortex Neoplasms | 2 | 2021 | 48 | 0.890 |
Why?
| | Adrenocortical Carcinoma | 2 | 2021 | 47 | 0.880 |
Why?
| | Thyroxine | 1 | 2023 | 59 | 0.860 |
Why?
| | Hypothyroidism | 1 | 2023 | 65 | 0.850 |
Why?
| | Melatonin | 7 | 2009 | 106 | 0.810 |
Why?
| | Proto-Oncogene Proteins B-raf | 6 | 2023 | 192 | 0.790 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2020 | 29 | 0.700 |
Why?
| | Circadian Rhythm | 8 | 2011 | 371 | 0.700 |
Why?
| | Splenectomy | 1 | 2020 | 54 | 0.690 |
Why?
| | Bacterial Vaccines | 1 | 2020 | 61 | 0.680 |
Why?
| | Dopamine | 9 | 2018 | 237 | 0.680 |
Why?
| | Biomarkers, Tumor | 4 | 2021 | 1048 | 0.660 |
Why?
| | Antigens, Neoplasm | 1 | 2020 | 223 | 0.640 |
Why?
| | Drug Resistance, Neoplasm | 3 | 2021 | 638 | 0.560 |
Why?
| | Pharmacogenomic Testing | 1 | 2016 | 54 | 0.530 |
Why?
| | Guideline Adherence | 1 | 2020 | 497 | 0.520 |
Why?
| | Databases, Genetic | 1 | 2016 | 208 | 0.500 |
Why?
| | Antineoplastic Agents | 2 | 2016 | 1893 | 0.500 |
Why?
| | NF-kappa B | 2 | 2015 | 639 | 0.480 |
Why?
| | Mutation | 9 | 2021 | 3364 | 0.460 |
Why?
| | Sepsis | 1 | 2020 | 515 | 0.460 |
Why?
| | Photoreceptor Cells, Vertebrate | 3 | 2012 | 25 | 0.450 |
Why?
| | Data Collection | 1 | 2016 | 636 | 0.440 |
Why?
| | Genetic Variation | 1 | 2018 | 877 | 0.430 |
Why?
| | Practice Guidelines as Topic | 1 | 2020 | 1405 | 0.410 |
Why?
| | Photoreceptor Cells | 3 | 2008 | 12 | 0.400 |
Why?
| | Genomics | 4 | 2024 | 645 | 0.400 |
Why?
| | Signal Transduction | 4 | 2018 | 4541 | 0.350 |
Why?
| | Eye Proteins | 3 | 2008 | 73 | 0.340 |
Why?
| | Adenocarcinoma, Follicular | 2 | 2019 | 34 | 0.330 |
Why?
| | GTP-Binding Protein Regulators | 1 | 2008 | 2 | 0.320 |
Why?
| | Cell Line, Tumor | 8 | 2021 | 2751 | 0.320 |
Why?
| | Oncogene Proteins, Fusion | 2 | 2021 | 178 | 0.310 |
Why?
| | Arylalkylamine N-Acetyltransferase | 2 | 2006 | 2 | 0.300 |
Why?
| | 14-3-3 Proteins | 1 | 2006 | 13 | 0.280 |
Why?
| | Phosphoproteins | 1 | 2008 | 304 | 0.270 |
Why?
| | MAP Kinase Signaling System | 2 | 2023 | 275 | 0.240 |
Why?
| | Humans | 24 | 2024 | 115587 | 0.240 |
Why?
| | Kynuramine | 1 | 2003 | 1 | 0.230 |
Why?
| | Biological Clocks | 4 | 2008 | 39 | 0.230 |
Why?
| | Neoplasm Staging | 2 | 2018 | 1178 | 0.220 |
Why?
| | Computers | 1 | 2023 | 60 | 0.220 |
Why?
| | Levodopa | 2 | 2018 | 23 | 0.220 |
Why?
| | Dopamine Agents | 2 | 2018 | 13 | 0.220 |
Why?
| | Thyrotropin | 1 | 2023 | 100 | 0.210 |
Why?
| | Neoplasms | 1 | 2016 | 2118 | 0.210 |
Why?
| | 3,4-Dihydroxyphenylacetic Acid | 6 | 2011 | 17 | 0.210 |
Why?
| | Data Warehousing | 1 | 2022 | 6 | 0.200 |
Why?
| | Cloud Computing | 1 | 2022 | 8 | 0.200 |
Why?
| | Light | 4 | 2009 | 337 | 0.200 |
Why?
| | Retinal Rod Photoreceptor Cells | 3 | 2018 | 11 | 0.200 |
Why?
| | Immunohistochemistry | 5 | 2020 | 1642 | 0.190 |
Why?
| | Receptor, Melatonin, MT1 | 2 | 2011 | 5 | 0.190 |
Why?
| | Pheochromocytoma | 1 | 2021 | 54 | 0.180 |
Why?
| | MutS Homolog 2 Protein | 1 | 2020 | 12 | 0.180 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2020 | 14 | 0.180 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2021 | 147 | 0.180 |
Why?
| | Night Blindness | 2 | 2012 | 6 | 0.180 |
Why?
| | Paraganglioma | 1 | 2021 | 47 | 0.180 |
Why?
| | Calcitonin | 1 | 2020 | 23 | 0.180 |
Why?
| | Ultrasonography | 1 | 2024 | 641 | 0.180 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 1147 | 0.180 |
Why?
| | Precision Medicine | 1 | 2024 | 344 | 0.180 |
Why?
| | Neuroendocrine Tumors | 1 | 2021 | 83 | 0.180 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2021 | 165 | 0.180 |
Why?
| | Haemophilus influenzae type b | 1 | 2020 | 10 | 0.180 |
Why?
| | Receptors, Virus | 1 | 2020 | 75 | 0.180 |
Why?
| | Neisseria meningitidis | 1 | 2020 | 18 | 0.170 |
Why?
| | Trans-Activators | 2 | 2021 | 370 | 0.170 |
Why?
| | Organizational Case Studies | 1 | 2020 | 72 | 0.170 |
Why?
| | Myopia | 2 | 2012 | 37 | 0.170 |
Why?
| | Disease Susceptibility | 2 | 2020 | 316 | 0.170 |
Why?
| | Animals | 23 | 2021 | 32102 | 0.170 |
Why?
| | Sensitivity and Specificity | 1 | 2024 | 1718 | 0.170 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2020 | 157 | 0.160 |
Why?
| | Postoperative Complications | 2 | 2023 | 2161 | 0.160 |
Why?
| | Crk-Associated Substrate Protein | 1 | 2018 | 5 | 0.160 |
Why?
| | DNA Mutational Analysis | 1 | 2020 | 372 | 0.160 |
Why?
| | Focal Adhesion Kinase 1 | 1 | 2018 | 27 | 0.160 |
Why?
| | Immune System | 1 | 2020 | 173 | 0.160 |
Why?
| | Proto-Oncogene Proteins c-jun | 1 | 2018 | 47 | 0.160 |
Why?
| | Leukocytes | 1 | 2020 | 281 | 0.160 |
Why?
| | Streptococcus pneumoniae | 1 | 2020 | 133 | 0.160 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2024 | 863 | 0.160 |
Why?
| | src-Family Kinases | 1 | 2018 | 88 | 0.150 |
Why?
| | DNA Mismatch Repair | 1 | 2018 | 37 | 0.150 |
Why?
| | Pharmacogenomic Variants | 1 | 2018 | 34 | 0.150 |
Why?
| | Adrenal Cortex | 1 | 2018 | 32 | 0.150 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2019 | 228 | 0.150 |
Why?
| | Rod Opsins | 2 | 2009 | 7 | 0.150 |
Why?
| | Oncogenes | 1 | 2018 | 104 | 0.150 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2018 | 31 | 0.150 |
Why?
| | Neoplasm Grading | 1 | 2018 | 244 | 0.140 |
Why?
| | Dark Adaptation | 3 | 2018 | 13 | 0.140 |
Why?
| | Telomerase | 1 | 2019 | 206 | 0.140 |
Why?
| | Gene Frequency | 1 | 2018 | 485 | 0.140 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2018 | 161 | 0.140 |
Why?
| | Photic Stimulation | 2 | 2008 | 203 | 0.140 |
Why?
| | Mice | 13 | 2021 | 15052 | 0.140 |
Why?
| | Amino Acids | 1 | 2000 | 454 | 0.140 |
Why?
| | Gene Expression Profiling | 2 | 2020 | 1536 | 0.140 |
Why?
| | Electroretinography | 5 | 2018 | 40 | 0.140 |
Why?
| | Combined Modality Therapy | 2 | 2018 | 1127 | 0.130 |
Why?
| | Disease Progression | 2 | 2020 | 2418 | 0.130 |
Why?
| | Diabetic Retinopathy | 1 | 2018 | 149 | 0.130 |
Why?
| | Disease Management | 1 | 2020 | 563 | 0.130 |
Why?
| | Tumor Suppressor Proteins | 1 | 2018 | 286 | 0.130 |
Why?
| | Cell Proliferation | 3 | 2021 | 2194 | 0.130 |
Why?
| | Tyrosine 3-Monooxygenase | 3 | 2018 | 68 | 0.130 |
Why?
| | Caspase 7 | 1 | 2015 | 22 | 0.130 |
Why?
| | Clinical Trials as Topic | 1 | 2020 | 941 | 0.130 |
Why?
| | Bortezomib | 1 | 2015 | 41 | 0.130 |
Why?
| | Information Storage and Retrieval | 1 | 2016 | 109 | 0.130 |
Why?
| | Mice, Knockout | 6 | 2018 | 2604 | 0.130 |
Why?
| | Thyroidectomy | 1 | 2015 | 52 | 0.130 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2019 | 396 | 0.130 |
Why?
| | User-Computer Interface | 1 | 2016 | 145 | 0.130 |
Why?
| | Inhibitory Concentration 50 | 1 | 2015 | 77 | 0.130 |
Why?
| | Hypocalcemia | 1 | 2015 | 31 | 0.130 |
Why?
| | Genetic Testing | 1 | 2018 | 382 | 0.130 |
Why?
| | Radiation, Ionizing | 1 | 2015 | 73 | 0.130 |
Why?
| | Pharmacogenetics | 1 | 2016 | 151 | 0.130 |
Why?
| | Taxoids | 1 | 2015 | 94 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2019 | 449 | 0.120 |
Why?
| | Caspase 3 | 1 | 2015 | 237 | 0.120 |
Why?
| | Computational Biology | 1 | 2018 | 536 | 0.120 |
Why?
| | Cell Death | 1 | 2015 | 326 | 0.110 |
Why?
| | Promoter Regions, Genetic | 1 | 2018 | 1122 | 0.110 |
Why?
| | Macrophages | 1 | 2020 | 1284 | 0.110 |
Why?
| | Interleukin-8 | 1 | 2014 | 241 | 0.110 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 1361 | 0.110 |
Why?
| | Phosphorylation | 2 | 2008 | 1571 | 0.110 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 2 | 2012 | 225 | 0.110 |
Why?
| | Neoplasm Transplantation | 3 | 2019 | 235 | 0.110 |
Why?
| | Models, Biological | 1 | 2020 | 1646 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2015 | 348 | 0.100 |
Why?
| | Neovascularization, Pathologic | 1 | 2014 | 283 | 0.100 |
Why?
| | Mice, Nude | 3 | 2021 | 639 | 0.100 |
Why?
| | Retinal Bipolar Cells | 1 | 2012 | 6 | 0.100 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2353 | 0.100 |
Why?
| | Calcium | 2 | 2015 | 1103 | 0.100 |
Why?
| | Protein Kinase Inhibitors | 3 | 2023 | 790 | 0.100 |
Why?
| | Mice, Inbred C57BL | 5 | 2018 | 4773 | 0.100 |
Why?
| | Dopamine Agonists | 2 | 2008 | 31 | 0.090 |
Why?
| | Dopamine beta-Hydroxylase | 1 | 2010 | 12 | 0.090 |
Why?
| | Algorithms | 1 | 2018 | 1490 | 0.090 |
Why?
| | Disulfiram | 1 | 2010 | 13 | 0.090 |
Why?
| | Obesity | 1 | 2023 | 2517 | 0.090 |
Why?
| | Alcohol Deterrents | 1 | 2010 | 17 | 0.090 |
Why?
| | Prognosis | 1 | 2018 | 3339 | 0.090 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2012 | 192 | 0.090 |
Why?
| | Female | 7 | 2021 | 59913 | 0.090 |
Why?
| | Conditioning, Operant | 1 | 2010 | 99 | 0.090 |
Why?
| | Extinction, Psychological | 1 | 2010 | 80 | 0.080 |
Why?
| | Vision, Ocular | 1 | 2009 | 30 | 0.080 |
Why?
| | Chickens | 2 | 2006 | 183 | 0.080 |
Why?
| | Light Signal Transduction | 1 | 2009 | 4 | 0.080 |
Why?
| | Amacrine Cells | 1 | 2009 | 14 | 0.080 |
Why?
| | Cyclic AMP | 2 | 2006 | 227 | 0.080 |
Why?
| | Disease Models, Animal | 3 | 2019 | 3580 | 0.080 |
Why?
| | Cocaine | 1 | 2010 | 153 | 0.080 |
Why?
| | Rats | 4 | 2010 | 5034 | 0.080 |
Why?
| | Dopamine Antagonists | 1 | 2008 | 22 | 0.080 |
Why?
| | Male | 10 | 2020 | 55949 | 0.080 |
Why?
| | Receptors, Dopamine D4 | 1 | 2008 | 24 | 0.080 |
Why?
| | Cells, Cultured | 4 | 2014 | 3914 | 0.080 |
Why?
| | Chromatography, High Pressure Liquid | 3 | 2011 | 477 | 0.080 |
Why?
| | Visual Pathways | 1 | 2008 | 44 | 0.080 |
Why?
| | Retinal Diseases | 1 | 2008 | 77 | 0.070 |
Why?
| | Apoptosis | 3 | 2021 | 2377 | 0.070 |
Why?
| | Nerve Growth Factors | 1 | 2007 | 73 | 0.070 |
Why?
| | United States | 2 | 2020 | 12295 | 0.070 |
Why?
| | Retrospective Studies | 1 | 2023 | 12608 | 0.070 |
Why?
| | Mammals | 1 | 2008 | 251 | 0.070 |
Why?
| | Adenylyl Cyclases | 1 | 2006 | 84 | 0.070 |
Why?
| | RNA, Messenger | 6 | 2012 | 2574 | 0.070 |
Why?
| | Calmodulin | 1 | 2006 | 72 | 0.070 |
Why?
| | Middle Aged | 3 | 2021 | 26999 | 0.070 |
Why?
| | Arylamine N-Acetyltransferase | 1 | 2005 | 5 | 0.060 |
Why?
| | Imidazoles | 2 | 2021 | 217 | 0.060 |
Why?
| | Retinal Ganglion Cells | 1 | 2005 | 92 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2006 | 793 | 0.060 |
Why?
| | Early Growth Response Protein 1 | 1 | 2023 | 28 | 0.060 |
Why?
| | Phenotype | 2 | 2023 | 2829 | 0.060 |
Why?
| | Biological Specimen Banks | 1 | 2024 | 95 | 0.050 |
Why?
| | Fibronectins | 1 | 2023 | 108 | 0.050 |
Why?
| | Oximes | 1 | 2021 | 19 | 0.050 |
Why?
| | Retinal Degeneration | 2 | 2012 | 30 | 0.050 |
Why?
| | Protein Binding | 1 | 2006 | 1917 | 0.050 |
Why?
| | Indazoles | 1 | 2021 | 58 | 0.050 |
Why?
| | Homovanillic Acid | 1 | 2000 | 7 | 0.040 |
Why?
| | Oxidation-Reduction | 1 | 2003 | 924 | 0.040 |
Why?
| | Drug Synergism | 1 | 2021 | 317 | 0.040 |
Why?
| | Adrenal Gland Neoplasms | 1 | 2021 | 81 | 0.040 |
Why?
| | Lighting | 1 | 2000 | 25 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2021 | 148 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2021 | 850 | 0.040 |
Why?
| | Validation Studies as Topic | 1 | 2019 | 22 | 0.040 |
Why?
| | Rats, Wistar | 1 | 2000 | 368 | 0.040 |
Why?
| | Neurons | 1 | 2007 | 1298 | 0.040 |
Why?
| | Dasatinib | 1 | 2018 | 46 | 0.040 |
Why?
| | Piperazines | 1 | 2021 | 314 | 0.040 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2021 | 704 | 0.040 |
Why?
| | Luminescence | 1 | 2018 | 34 | 0.040 |
Why?
| | Aldosterone | 1 | 2018 | 42 | 0.040 |
Why?
| | Oscillometry | 1 | 2018 | 33 | 0.040 |
Why?
| | Cell Survival | 2 | 2012 | 1024 | 0.040 |
Why?
| | Germ-Line Mutation | 1 | 2018 | 131 | 0.040 |
Why?
| | Drug Interactions | 2 | 2010 | 347 | 0.040 |
Why?
| | Chick Embryo | 2 | 2006 | 122 | 0.030 |
Why?
| | Blotting, Western | 2 | 2011 | 1153 | 0.030 |
Why?
| | In Situ Hybridization | 2 | 2007 | 298 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 443 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 736 | 0.030 |
Why?
| | NF-KappaB Inhibitor alpha | 1 | 2014 | 52 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2007 | 930 | 0.030 |
Why?
| | Colorado | 1 | 2024 | 4113 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2651 | 0.030 |
Why?
| | I-kappa B Proteins | 1 | 2014 | 78 | 0.030 |
Why?
| | Human Umbilical Vein Endothelial Cells | 1 | 2014 | 90 | 0.030 |
Why?
| | Body Weight | 1 | 2018 | 867 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2018 | 9159 | 0.030 |
Why?
| | Mucoproteins | 1 | 2012 | 10 | 0.030 |
Why?
| | Opsins | 1 | 2012 | 10 | 0.030 |
Why?
| | Pineal Gland | 1 | 2012 | 12 | 0.030 |
Why?
| | Bromodeoxyuridine | 1 | 2012 | 73 | 0.030 |
Why?
| | Nerve Tissue Proteins | 2 | 2006 | 535 | 0.030 |
Why?
| | Oncogene Proteins | 1 | 2012 | 53 | 0.030 |
Why?
| | Microarray Analysis | 1 | 2012 | 119 | 0.030 |
Why?
| | Microscopy, Electron, Transmission | 1 | 2012 | 138 | 0.030 |
Why?
| | Eye Diseases, Hereditary | 1 | 2012 | 12 | 0.030 |
Why?
| | Neoplasm Metastasis | 1 | 2014 | 526 | 0.030 |
Why?
| | Genetic Diseases, X-Linked | 1 | 2012 | 22 | 0.030 |
Why?
| | Receptors, Metabotropic Glutamate | 1 | 2012 | 35 | 0.020 |
Why?
| | Transcription Factors | 2 | 2012 | 1528 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2012 | 244 | 0.020 |
Why?
| | Heterozygote | 1 | 2012 | 252 | 0.020 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 302 | 0.020 |
Why?
| | Chromosome Mapping | 1 | 2012 | 489 | 0.020 |
Why?
| | Pedigree | 1 | 2012 | 467 | 0.020 |
Why?
| | Thiones | 1 | 2010 | 14 | 0.020 |
Why?
| | Self Administration | 1 | 2010 | 124 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2012 | 374 | 0.020 |
Why?
| | Norepinephrine | 1 | 2010 | 207 | 0.020 |
Why?
| | Darkness | 1 | 2009 | 23 | 0.020 |
Why?
| | Analysis of Variance | 1 | 2012 | 1227 | 0.020 |
Why?
| | GTP-Binding Protein alpha Subunits | 1 | 2009 | 12 | 0.020 |
Why?
| | Adaptation, Biological | 1 | 2009 | 54 | 0.020 |
Why?
| | Transducin | 1 | 2009 | 40 | 0.020 |
Why?
| | Retinal Cone Photoreceptor Cells | 1 | 2009 | 14 | 0.020 |
Why?
| | Food | 1 | 2010 | 160 | 0.020 |
Why?
| | Blood Glucose | 1 | 2018 | 1824 | 0.020 |
Why?
| | CLOCK Proteins | 1 | 2008 | 7 | 0.020 |
Why?
| | Periodicity | 1 | 2008 | 56 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2015 | 3022 | 0.020 |
Why?
| | Zebrafish | 1 | 2012 | 412 | 0.020 |
Why?
| | Sensory Deprivation | 1 | 2008 | 8 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-fos | 1 | 2009 | 181 | 0.020 |
Why?
| | Feedback, Physiological | 1 | 2008 | 73 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2008 | 271 | 0.020 |
Why?
| | Proteoglycans | 1 | 2008 | 107 | 0.020 |
Why?
| | Calcium Channel Agonists | 1 | 2006 | 10 | 0.020 |
Why?
| | Flavoproteins | 1 | 2006 | 7 | 0.020 |
Why?
| | Risk Assessment | 1 | 2015 | 2987 | 0.020 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2007 | 106 | 0.020 |
Why?
| | ARNTL Transcription Factors | 1 | 2006 | 15 | 0.020 |
Why?
| | 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine | 1 | 2005 | 1 | 0.020 |
Why?
| | Calcium Channel Blockers | 1 | 2006 | 115 | 0.020 |
Why?
| | Quinpirole | 1 | 2005 | 9 | 0.020 |
Why?
| | Cryptochromes | 1 | 2006 | 23 | 0.020 |
Why?
| | Photoperiod | 1 | 2006 | 52 | 0.020 |
Why?
| | Kainic Acid | 1 | 2005 | 31 | 0.020 |
Why?
| | Cell Nucleus | 1 | 2009 | 553 | 0.020 |
Why?
| | Excitatory Amino Acid Agonists | 1 | 2005 | 37 | 0.020 |
Why?
| | Microscopy, Confocal | 1 | 2007 | 299 | 0.020 |
Why?
| | Rats, Inbred F344 | 1 | 2005 | 245 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2262 | 0.020 |
Why?
| | Receptors, Dopamine D2 | 1 | 2005 | 85 | 0.020 |
Why?
| | Animals, Newborn | 1 | 2007 | 780 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2006 | 211 | 0.020 |
Why?
| | Prospective Studies | 1 | 2015 | 6264 | 0.010 |
Why?
| | Physical Conditioning, Animal | 1 | 2006 | 191 | 0.010 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 1870 | 0.010 |
Why?
| | Gene Expression | 1 | 2006 | 1435 | 0.010 |
Why?
| | Aged | 1 | 2019 | 19251 | 0.010 |
Why?
| | Membrane Proteins | 1 | 2006 | 1024 | 0.010 |
Why?
| | Aging | 1 | 2009 | 1631 | 0.010 |
Why?
| | Brain | 1 | 2010 | 2370 | 0.010 |
Why?
| | Time Factors | 1 | 2005 | 6165 | 0.010 |
Why?
|
|
Pozdeyev's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|